Solid pharmaceutical formulation for the treatment of endometriosis, uterine fibrosis, polycystic ovary syndrome or adenomyosis

• 1. 用于治疗子宫腺肌病及子宫内膜异位症的装置及相关应用 [P] . 中国专利： CN101291632A . 2008-10-22
• 2. 一种治疗子宫内膜异位症、子宫腺肌病的药物组合物及其制备方法和用途 [P] . 中国专利： CN104740536A . 2015-07-01
• 3. Pharmaceutical formulation for the treatment of endometriosis, uterine fibrosis, polycystic ovary syndrome or adenomyosis [P] . 韩国专利： KR20200109291A . 2020-09-22

  机译： 用于治疗子宫内膜异位，子宫纤维化，多囊卵巢综合征或子宫腺肌病的药物制剂

• 4. solid pharmaceutical formulations to treat endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis [P] . BR112020003388A2 . 2020-08-25

  机译： 用于治疗子宫内膜异位症，子宫肌瘤，多囊卵巢综合征和子宫腺肌病的固体药物制剂

• 5. Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis [P] . AU2018317473A1 . 2020-03-05

  机译： 用于治疗子宫内膜异位症，子宫肌瘤，多囊卵巢综合征和子宫腺肌病的固体药物制剂

• 1. Hospital-Based Phenotypic Features and Treatment Outcomes of Chinese Women with Polycystic Ovary Syndrome: The Effect of Body Mass Index and Geographic Distribution [J] . Jingshu Gao, Hongli Ma, Yu Wang, 工程（英文） . 2021,第002期
• 2. Nutraceutical Treatment of Patients with Polycystic Ovary Syndrome [J] . Comhaire Frank, Decleer Wim 妇产科期刊（英文） . 2021,第009期
• 3. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome [J] . LegroR.S., KunselmanA.R., BrzyskiR.G., Contemporary clinical trials . 2012,第3期
• 4. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. [J] . Moran LJ, Pasquali R, Teede H Fertility and Sterility: Official Journal of the American Fertility Society, Pacific Coast Fertility Society, and the Canadian Fertility and Andrology Society . 2009,第6期
• 5. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. [J] . Uras R, Orru M, Pani F, Contraception . 2010,第2期
• 6. Evaluation of Label Drug in the Treatment Polycystic Ovary Syndrome [C] . Keni Idacahyati, Tita Nofianti, Ema Sintya Nurjaya Bakti Tunas Husada-Health Science International Conference . 2020
• 7. Validation of the obese Ossabaw miniature pig as a model of the obese polycystic ovary syndrome phenotype with concomitant metabolic syndrome: Exploration of polycystic ovary syndrome pathophysiology using in vivo and in vitro models [D] . Newell-Fugate, Anne Elizabeth 2012
• 8. THE PREGNANCY IN POLYCYSTIC OVARY SYNDROME II (PPCOS II) TRIAL: RATIONALE AND DESIGN OF A DOUBLE-BLIND RANDOMIZED TRIAL OF CLOMIPHENE CITRATE AND LETROZOLE FOR THE TREATMENT OF INFERTILITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME [O] . Richard S. Legro, Allen R. Kunselman, Robert G. Brzyski, -1
• 9. Irritable bowel syndrome, endometriosis and polycystic ovary syndrome: is there a link? [O] . Ashwath Narayan Ramji 2019

• 1. Meta Analysis of the Efficacy of Nonpharmaceutical Chinese Medicine Therapy in the Treatment of Obese Polycystic Ovary Syndrome [J] . Shirong Liu ,Nan Li . 临床护理研究 . 2022,第1期
• 2. Treatment of Polycystic Ovary Syndrome from the Theory of "Yigui Homology" [J] . Xin Zhao ,Mei Chen ,Nan Li . 临床护理研究 . 2021,第003期
• 3. Research Progress of Non-drug Therapy of Traditional Chinese Medicine in the Treatment of Obese Polycystic Ovary Syndrome [J] . Chanchan Li ,Nan Li . 临床护理研究 . 2021,第004期
• 4. 14.子宫内膜异位症和子宫腺肌病治疗进展 [C] . 周应芳 . 第三次全国妇产科基层医师学术会议 . 2005
• 5. 清湿化瘀法治疗子宫内膜异位症和子宫腺肌病的临床研究 [A] . 莫冬梅 . 2017